| 4.995 -0.095 (-1.87%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.07 |
1-year : | 8.14 |
| Resists | First : | 6.05 |
Second : | 6.96 |
| Pivot price | 5.23 |
|||
| Supports | First : | 4.57 |
Second : | 3.8 |
| MAs | MA(5) : | 4.95 |
MA(20) : | 5.37 |
| MA(100) : | 9.55 |
MA(250) : | 13.55 |
|
| MACD | MACD : | -0.6  |
Signal : | -0.7 |
| %K %D | K(14,3) : | 32.2 |
D(3) : | 25.8 |
| RSI | RSI(14): 34.8 |
|||
| 52-week | High : | 21.04 | Low : | 4.57 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CDMO ] has closed above bottom band by 28.1%. Bollinger Bands are 47.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.34 - 5.36 | 5.36 - 5.38 |
| Low: | 4.88 - 4.9 | 4.9 - 4.93 |
| Close: | 5.05 - 5.09 | 5.09 - 5.12 |
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Fri, 01 Dec 2023
Uber Technologies, Jabil and Builders FirstSource Set to Join S&P ... - PR Newswire
Thu, 30 Nov 2023
Avid Bioservices to Report Financial Results for Second Quarter of ... - Yahoo Finance
Mon, 27 Nov 2023
Is it Time to Dump Avid Bioservices Inc (CDMO) Stock After it Has Fallen 11.53% in a Week? - InvestorsObserver
Mon, 27 Nov 2023
From laggards to leaders: Small caps on the rise - The Globe and Mail
Wed, 15 Nov 2023
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study - Nasdaq
Tue, 14 Nov 2023
Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 108.1 (%) |
| Shares Short | 5,390 (K) |
| Shares Short P.Month | 5,140 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.01 |
| Profit Margin | -2.1 % |
| Operating Margin | -5.8 % |
| Return on Assets (ttm) | -0.2 % |
| Return on Equity (ttm) | -1.7 % |
| Qtrly Rev. Growth | 2.7 % |
| Gross Profit (p.s.) | 0.49 |
| Sales Per Share | 2.38 |
| EBITDA (p.s.) | 0.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -102 (M) |
| PE Ratio | -99.9 |
| PEG Ratio | -3.1 |
| Price to Book value | 1.65 |
| Price to Sales | 2.09 |
| Price to Cash Flow | -38.78 |
| Dividend | 0.66 |
| Forward Dividend | 0 |
| Dividend Yield | 13.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|